INT176146

Context Info Confidence 0.36 First Reported 2004 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 3 Total Number 4 Disease Relevance 1.69 Pain Relevance 0.50

lipid binding (PTEN) cell proliferation (PTEN) cytosol (PTEN) plasma membrane (PTEN) nucleus (PTEN) enzyme binding (PTEN)

Anatomy Link Frequency arm 4 PTEN (Homo sapiens)

Pain Link Frequency Relevance Heat rheumatoid arthritis 108 98.90 antagonist 22 92.96 spinal inflammation 62 50.00 agonist 6 50.00 methotrexate 106 46.48 cytokine 4 34.68 Inflammation 42 24.60 Arthritis 68 19.52 Infliximab 14 5.00 Adalimumab 10 5.00

Disease Link Frequency Relevance Heat Rheumatoid Arthritis 108 98.90 Endometrial Cancer 20 89.60 Cancer 83 86.24 Infection 12 65.04 Stress 13 62.08 Low Back Pain 66 50.00 INFLAMMATION 39 24.60 Seronegative Spondarthritis 62 20.32 Apoptosis 23 16.20 Nail Diseases 4 6.96

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

On the opposite, the presence of a mutated PTEN protein enables Akt phosphorylation, which in turn may phosphorylate I?

Positive_regulation (enables) of Localization (presence) of PTEN

1) Confidence 0.36 Published 2004 Journal Mol Cancer Section Body Doc Link PMC394342 Disease Relevance 0.23 Pain Relevance 0

of IkB, induction of TSC22, NF-kB, GADD153, PTEN, etc.) may depend on the

Positive_regulation (induction) of Localization (etc.) of PTEN

2) Confidence 0.25 Published 2008 Journal PPAR Research Section Body Doc Link PMC2464819 Disease Relevance 0.80 Pain Relevance 0

therapy and discontinued for any reason, GLM significantly reduced signs and symptoms of RA and improved physical function at week 24 as assessed by ACR20, ACR50, and improvement in HAQ scores (P <0.001 for all measures for each GLM treatment arm compared individually with placebo).25 Among patients who had discontinued prior TNF-?

Positive_regulation (by) of Localization (arm) of GLM in arm associated with rheumatoid arthritis

3) Confidence 0.07 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.36 Pain Relevance 0.27

therapy and discontinued for any reason, GLM significantly reduced signs and symptoms of RA and improved physical function at week 24 as assessed by ACR20, ACR50, and improvement in HAQ scores (P <0.001 for all measures for each GLM treatment arm compared individually with placebo).25 Among patients who had discontinued prior TNF-?

Positive_regulation (measures) of Localization (arm) of GLM in arm associated with rheumatoid arthritis

4) Confidence 0.07 Published 2010 Journal Core evidence Section Body Doc Link PMC2899784 Disease Relevance 0.30 Pain Relevance 0.24

General Comments

This test has worked.